Abstract: An unevenness correction data generation device suppressing the appearance of color unevenness when turning on R, G and B together includes a pattern generation unit causing red, green and blue images, in which display panel subpixels are turned on at the same gray level, to be displayed, a monochrome camera, a control unit generating first red, green and blue luminance correction data based on shooting data of the monochrome camera, a pattern generation unit causing the display panel to display a white image by causing red, green and blue images corrected with the respective luminance correction data to be displayed simultaneously, a color camera shooting the white image in color, and a control unit generating color correction data for correcting color unevenness based on shooting data of the color camera and generates unevenness correction data based on the red, green and blue luminance correction data and the color correction data.

Abstract: A method of extracting fucoidan from a biological material is provided. The method comprises (a) combining a biological material containing fucoidan and a medium to form a mixture; (b) applying ultrasonic waves to the mixture while the mixture is at a temperature of less than about 60 C; (c) extracting fucoidan into the medium from the biological material to produce a fucoidan containing solution and insoluble biological matter; and (d) separating the fucoidan containing solution from the insoluble biological matter to obtain a fucoidan containing extract. Methods of using the fucoidan containing extract and pharmaceutical preparations containing the fucoidan containing extract are also provided.

Abstract: A method of extracting fucoidan from a biological material is provided. The method comprises (a) combining a biological material containing fucoidan and a medium to form a mixture; (b) applying ultrasonic waves to the mixture while the mixture is at a temperature of less than about 60 C; (c) extracting fucoidan into the medium from the biological material to produce a fucoidan containing solution and insoluble biological matter; and (d) separating the fucoidan containing solution from the insoluble biological matter to obtain a fucoidan containing extract. Methods of using the fucoidan containing extract and pharmaceutical preparations containing the fucoidan containing extract are also provided.

Abstract: A process for preparing olefinic living polymers having a molecular weight distribution (Mw/Mn) of 1 to 1.3, comprising polymerizing an olefinic monomer having 2 to 20 carbon atoms at low temperatures in the presence of a catalyst comprising (A) a hafnium or zirconium-containing compound having one or two cyclopentadienyl backbones, (B) a triphenyl boron compound or a tetraphenyl borate compound and optionally (C) a specific mono-, di- or trialkylaluminum compound. When the catalyst comprising the zirconium-containing compound is prepared by further using a titanium-containing compound (D), the polymerization temperature can be raised.

Abstract: According to the present invention, production processes for pickled egg powder which includes either adding an aqueous solution of edible acid to whole eggs (including egg shell) at a rate of at least 150 ml per 100 g of the whole eggs, effecting the pickling treatment at temperatures of from about 0° to about 50° C., optionally filtering the so formed pickled egg solution and spray-drying the same under the conditions of an inlet temperature of at least 180° C. and an outlet temperature of at least 120° C.; or adding an aqueous solution of edible acid and hydrolytic enzyme to whole eggs (including a egg shell), carrying out the decomposition treatment at temperatures of from about 0° to about 50° C., optionally heat-sterilizing and/or filtering the so formed liquid decomposition product, and powderizing the same by drying, are provided.

Abstract: The present invention provides a novel polypeptide which has fish growth hormone-like activity and which can be widely used no matter what the species of fish is.

Abstract: A stabilized human monoclonal antibody preparation containing 1 to 20 mg of D-mannitol per 1 mg of a human monoclonal antibody. This preparation is excellent in stability in a solution state, a freeze drying state and a freezing state, particularly stability against aggregation and precipitation of the human monoclonal antibody at the time of redissolution after freeze drying.

Abstract: CLNH5-specific hybridomas, human monoclonal antibodies and their uses are provided. The antibodies distinguish a human neoplastic cell from a normal cell of the same tissue type. The monoclonal antibodies find use in therapy and diagnosis, both in vitro and in vivo.

Abstract: CLNH11-specific hybridomas, human monoclonal antibodies and their uses are provided. The antibodies distinguish a human neoplastic cell from a normal cell of the same tissue type. The monoclonal antibodies find use in therapy and diagnosis, both in vitro and in vivo.

Abstract: CLNH5 and CLNH11 specific hybridomas, human monoclonal antibodies and their uses are provided. The antibodies distinguish a human neoplastic cell from a normal cell of the same tissue type. The monoclonal antibodies find use in therapy and diagnosis, both in vitro and in vivo.

Abstract: CLNH5 and CLNH11-specific hybridomas, human monoclonal antibodies and their uses are provided. The antibodies distinguish a human neoplastic cell from a normal cell of the same tissue type. The monoclonal antibodies find use in therapy and diagnosis, both in vitro and in vivo.

Abstract: A vector plasmid containing(a) the OriA region of plasmid pBA1 derived from Anacystis nidulans,(b) the multicloning region and(c) the region of colicin E1 plasmid, which contains the OriE region thereof and wherein the gene defined by the rop region thereof is removed.This plasmid is replicable in the cells of both Escherichia coli and cyanobacteria and thus useful as a shuttle vector.

Abstract: A method for expressing a physiologically active polypeptide in cells of a blue-green alga by transforming the cells of a blue-green alga with a recombinant DNA containing a structural gene encoding the polypeptide, characterized in that as the recombinant DNA is used a recombinant DNA which contains a structural gene encoding the physiologically active polypeptide, the transcription initiation region of the RuBisCO gene of Anacystis nidulans located upstream of the structural gene, and the transcription termination region of the RuBisCO gene located downstream of the structural gene. According to this method, physiologically active polypeptide can efficiently be expressed using blue-green algae.

Abstract: Two penta-peptides, Asp-Asp-Asn-Asp-Asn and Asp-Asp-Ser-Gln-Gln, extracted from green barley leaves, have been found to inhibit the adenosine diphosphate (ADP)-induced aggregation of human blood platelets.

Abstract: A new cell line TriH8 is obtained by fusing a particular sub-clone, A431c, of the human epidermoid carcinoma cell line A431 with the TOS/H8 (human/human) hybridoma. Fused cell TriH8 has been deposited under FRI accession number FERM BP-4452. The fused cell is capable of proliferating in basal medium without addition of serum or growth factor. The cell line is more effective in producing antibody (IgM) than the donor cell TOS/H8.

Abstract: An agent for preserving the freshness of plants containing 2"-O-glucosylisovitexin as an effective ingredient is disclosed. This agent is excellent in an effect of preserving the freshness of cut flowers and potted plants, and, moreover, is safe and has no problem of the pollution of the environment.

Abstract: Amino acid sequences of the H chain and L chain variable regions of mouse monoclonal antibodies Idio 3, Idio 17, Idio 20, Idio 27 and Idio 33 against idiotypes of a cancer cell antigen-specific human immunoglobulin CLN/IgG produced by a human/human fused cell strain CLN/SUZ H11, and base sequences of the genes of the variable regions are disclosed. The above amino acid sequences and the base sequences are useful in medical and pharmaceutical fields such as prophylaxis, treatment and/or diagnosis of human diseases, and/or in pharmacological and/or biochemical fields, etc. such as biochemical reagents, and reagents for purification of biomacromolecules.

Abstract: Powders of plant green juice having an improved stability and tastiness which are storable for a long period of time, characterized in that said powders comprise:(a) dry powders of the plant green juice obtained by squeezing fresh raw edible green plants and(b) a water-soluble alkaline naturally occurring mineral mixture dispersed uniformly in said dry powder,and the pH of a dispersion at the time of dispersing in water falls into a range of 6.2-9.5. The powders can be produced by adding a water-soluble alkaline naturally occurring mineral mixture to a plant green juice obtained by squeezing fresh raw edible green plants thereby to adjust the pH of said plant green juice to be a range of 6-9 and then spray-drying or lyophilizing the green juice.

Abstract: A pressed juice of green leaves of true grasses or its dry powder wherein the total amount of chlorine (Cl) and nitrate group (NO.sub.3) is not more than 9% by weight based on the solids content, and a process for producing same using an ion exchange membrane or an ion exchange resin. The above pressed juice or its dry powder is substantially free from additives as a natural food, has less amounts of chlorine and nitrate group which are undesirous to a human body, is improved in palatability and preservability, and is useful in the field of food, food additives, drugs, or the like.